A Comparison of Paliperidone and Risperidone for Treatment of Patirnts With Methamphetamine-Associated Psychosis
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
Methamphetamine-associated psychosis (MAP) has been considered a pharmacological or
environmental pathogen model of schizophrenia (SCZ) due in part to similarities in clinical
presentation (i.e. paranoia, hallucinations, disorganized speech, and negative symptoms),
response to treatment (e.g.neuroleptics),and pathologic mechanisms (e.g. central dopaminergic
neurotransmission) of both conditions. Both paliperidone and risperidone are second
generation antipsychotics，but have same pharmacological effects of antipsychotic treatment
and paliperidone may have more efficacy and safty.This study was designed to examine the
acute efficacy, safety, and tolerability of paliperidone and risperidone for patients with
MAP.